Zafgen Stock Company Profile

Description

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate is the Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in patients with Prader-Willi syndrome; that has completed Phase II clinical trials to treat hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which has completed Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor that is in pre-clinical studies for the treatment of nonalcoholic steatohepatitis and abdominal obesity, as well as other second-generation MetAP2 inhibitors to treat severe obesity. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.